Format

Send to

Choose Destination
Biotechnol Bioeng. 2008 Oct 15;101(3):429-34. doi: 10.1002/bit.22056.

Polyvalency: a promising strategy for drug design.

Author information

1
The Howard P. Isermann Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, 110, 8th Street, Ricketts Building, Troy, New York 12180, USA.

Abstract

The simultaneous binding of multiple ligands on one entity to multiple receptors on another can result in an affinity that is significantly greater than that for the binding of a single ligand to a single receptor. This concept of "polyvalency" can be used to design molecules that are potent inhibitors of toxins and pathogens. We describe the design of potent polyvalent inhibitors that neutralize anthrax toxin in vivo as well as our attempts to elucidate the relationship between inhibitor structure and activity. We also highlight promising future avenues for research in polyvalent drug design.

PMID:
18727104
DOI:
10.1002/bit.22056
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center